Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07022275 · ClinicalTrials.gov registry record · NA
Safety Evaluation of THC-Free Hemp Protein Isolate
A NA study of Tolerability of Hemp Protein, sponsored by National University of Natural Medicine.
- Active
- Registry status
- NA
- Development phase
- 32
- Enrollment target
- 1
- Study location
NCT07022275: Active NA study of Tolerability of Hemp Protein, sponsored by National University of Natural Medicine.
NCT07022275 is a NA study of Tolerability of Hemp Protein that is active but no longer recruiting, run by National University of Natural Medicine. The registered enrollment target is 32 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07022275, a NA study of Tolerability of Hemp Protein, is active but no longer recruiting, sponsored by National University of Natural Medicine.
- ACTIVE NOT RECRUITING
- Registry status
- NA
- Development phase
- 32 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this clinical trial is to evaluate the safety and tolerability of a THC-free hemp protein supplement in healthy adult volunteers aged 18-65 years who do not use cannabis or hemp-derived products. The main questions this study aims to answer are: Does twice-daily consumption of 20 grams of Agoge Hemp Protein Powder for 30 days result in detectable levels of THC-COOH, the primary metabolite of THC, in urine samples? Is the supplement well tolerated, and does it affect common clinical safety markers (e.g., liver and kidney function, inflammatory markers)? This is a single-arm study with no comparison group. All participants will: * Consume 20 grams of the hemp protein supplement twice daily for 30 days * Provide blood and urine samples at baseline and Day 30 * Complete weekly surveys assessing adherence, tolerability, and adverse events
Primary Outcome
To determine whether THC-COOH, the primary metabolite of THC, is detectable in participants' urine after 30 days of consuming 40 grams of Agoge Hemp Protein Powder.
Conditions Studied
Interventions
- DIETARY_SUPPLEMENT Hemp protein powder
Study Locations (1)
Oregon
- Helfgott Research Institute - Portland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2025-03-15 |
| Est. Completion | 2025-09-25 |
| Phase | NA |
What the registry record for NCT07022275 still lists
NCT07022275 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 32 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower).
The record links to 1 condition, with Tolerability of Hemp Protein appearing as the primary indexed condition, and to 1 intervention - of which Hemp protein powder is the first listed.
NCT07022275 reports a single indexed study location in Oregon.
Frequently Asked Questions
What is clinical trial NCT07022275 about?
NCT07022275 is a clinical study titled "Safety Evaluation of THC-Free Hemp Protein Isolate". The goal of this clinical trial is to evaluate the safety and tolerability of a THC-free hemp protein supplement in healthy adult volunteers aged 18-65 years who do not use cannabis or hemp-derived products. The main questions this study aims to answer are: Does twice-daily consumption of 20 grams ...
What is the current status of trial NCT07022275?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 32 participants. The study started on 2025-03-15. Estimated completion is 2025-09-25.
What conditions does trial NCT07022275 study?
This clinical trial studies the following conditions: Tolerability of Hemp Protein.
What interventions are being tested in trial NCT07022275?
The interventions under investigation include: Hemp protein powder (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT07022275?
This trial is sponsored by National University of Natural Medicine, which has 30 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07022275 being conducted?
This trial has 1 study location across Oregon. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07022275's enrollment target sits among peer trials
32 1578th of 2000 higher than 409 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02445781 · 32 participants · Early Phase 1
Differing Levels of Hypoglycemia
- NCT02792270 · 32 participants · NA
Caloric Restriction In Sarcoma Patients Treated With Pre-Operative RT
- NCT03068910 · 32 participants · Early Phase 1
Hyperandrogenemia and Altered Day-night LH Pulse Patterns
- NCT03208868 · 32 participants · NA
Leucine Enriched Essential Amino Acid Mixture to Reverse Muscle Loss in Cirrhosis
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI